Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Adcentrx and Adcendo score millions in funding for antibody-drug conjugate work

by Megha Satyanarayana
May 7, 2021 | A version of this story appeared in Volume 99, Issue 17

 

Two biotech companies have each raised tens of millions in series A funding to develop antibody-drug conjugates (ADCs). San Diego–based Adcentrx Therapeutics will receive $50 million for cancer-fighting ADCs that use what company founder Hui Li calls a proprietary conjugation platform. Copenhagen-based Adcendo will receive $62 million to advance its ADCs, including one that targets a novel cancer marker—a collagen-scavenging protein called uPARAP/Endo180.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.